Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.

Trial Details

NCT ID

NCT06435260

Phase

PHASE2

Sponsor

Hebei Medical University Fourth Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Camrelizumab+chemotherapy
hypofractionated radiotherapy

Locations (sample)

Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

Age:18 to 75 years old, male or female;
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Tumor was located in the pancreas;
Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →